MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study

por Zacharieva, Sabina Z, Pivonello, Rosario, Elenkova, Atanaska, Tóth, Miklós, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin P, Brue, Thierry, Georgescu, Carmen Emanuela, Cohen, Fredric J, Fleseriu, Maria
Publicado 2020

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study

por Zacharieva, Sabina, Pivonello, Rosario, Elenkova, Atanaska, Toth, Miklos, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin P, Brue, Thierry Christian, Georgescu, Carmen Emanuela, Tsagarakis, Stylianos, Cohen, Fredric J, Fleseriu, Maria
Publicado 2021

Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study

por Nieman, Lynnette K, Boscaro, Marco, Scaroni, Carla Maria, Deutschbein, Timo, Mezosi, Emese, Driessens, Natacha, Georgescu, Carmen Emanuela, Hubalewska-D, Alicja, Berker, Dilek, Jarzab, Barbara Maria, Maiter, Dominique M, Reincke, Martin, Loli, Paola, Zampetti, Benedetta, Atmaca, Ayşegül, Badiu, Corin P, Beckers, Albert M, Bolanowski, Marek, Cavagnini, Francesco, Unger, Nicole, Giordano, Roberta, Hanzu, Felicia Alexandra, Terzolo, Massimo, Bostnavaron, Martine, Toth, Miklos
Publicado 2021